KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Operating Expenses: 2010-2025

Historic Operating Expenses for TherapeuticsMD (TXMD) over the last 13 years, with Sep 2025 value amounting to $1.6 million.

  • TherapeuticsMD's Operating Expenses fell 2.08% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 45.31%. This contributed to the annual value of $6.5 million for FY2024, which is 33.63% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Operating Expenses is $1.6 million, which was down 0.06% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Operating Expenses ranged from a high of $60.0 million in Q3 2021 and a low of -$77.8 million during Q4 2021.
  • Moreover, its 3-year median value for Operating Expenses was $1.7 million (2024), whereas its average is $1.9 million.
  • Per our database at Business Quant, TherapeuticsMD's Operating Expenses tumbled by 250.77% in 2021 and then surged by 125.87% in 2022.
  • Quarterly analysis of 5 years shows TherapeuticsMD's Operating Expenses stood at -$77.8 million in 2021, then soared by 125.87% to $20.1 million in 2022, then tumbled by 89.50% to $2.1 million in 2023, then plummeted by 101.56% to -$33,000 in 2024, then declined by 2.08% to $1.6 million in 2025.
  • Its Operating Expenses stands at $1.6 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.3 million for Q1 2025.